Bristol-Myers Squibb trades at a forward P/E of roughly 8.6x. That’s a pharma giant with about $128 billion in market cap, a dividend yield of roughly 4.0%, and a pipeline the Street is only partially giving credit for. The stock has actually outperformed the S&P 500 over the past 52 weeks, up about 24%, but the persistent discount to peers reflects a real concern: the patent cliff.
Revlimid, Pomalyst, Sprycel, and Abraxane are all facing generic erosion. The legacy portfolio is expected to decline 12% to 16% in 2026. That’s not a rumor. Management built it into guidance when they put out the full-year ~$46 to $47.5 billion revenue range, down from $48.2 billion in 2025. So the bad news is, in a sense, already in the model.
What’s less priced in is what’s going the other way.
The Growth Portfolio Is the Real Story
In Q1 2026, Bristol-Myers’ growth portfolio hit $6.23 billion, up 12% year over year. For the first time, newer drugs made up more than half of total quarterly revenue. That’s a structural inflection point, not a footnote. The trio driving it was Camzyos, Breyanzi, and Reblozyl, with combined sales of about $1.28 billion in Q1, up roughly 43% year over year. Eliquis added $4.14 billion in Q1 sales.
Opdivo is the one franchise that’s been messier. Q1 Opdivo revenue came in around $2.15 billion, down 5% year over year, with management citing sales channel inventory changes and timing. That’s possible. But if Opdivo doesn’t reaccelerate in Q2, that’s a real hole, because Opdivo is still one of the few products large enough to materially cushion the legacy erosion. Analysts are watching the Opdivo number closely on July 30.
The Pipeline Has Legs
Here’s where it gets interesting. The bear case on BMY for years has been that the pipeline wasn’t good enough to replace the drugs going off patent. That argument is weakening. The FDA granted Priority Review to Camzyos for adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy, with a target action date of September 30, 2026. If approved, Camzyos would become the first cardiac myosin inhibitor available for that population, extending the franchise into a younger patient segment.
Then there’s the Hengrui deal: BMS committed up to $950 million near term, including $600 million upfront, with total deal value reaching roughly $15.2 billion across oncology, hematology, and immunology. That’s not a small bet. Management is signaling that the business development pipeline is active.
Phase 3 data is also moving. Izalontamab brengitecan showed statistically significant improvements in overall survival and progression-free survival in triple-negative breast cancer and esophageal squamous cell carcinoma. Milvexian Phase III data is expected in H2 2026. Mezigdomide is generating positive early data in multiple myeloma. These aren’t speculative programs. They’re late-stage assets with real probability of commercial launch.
What Q2 Needs to Show
Consensus for Q2 is $1.60 adjusted EPS, up 10.3% from the year-ago quarter, on revenue of $11.74 billion. BMY has beaten EPS estimates in each of its last four quarters. The full-year EPS guidance range of $6.05 to $6.35 is what investors are watching for any revision.
The key signals on July 30: Eliquis trajectory into the IRA pricing negotiation period, Opdivo domestic demand, Camzyos quarterly run rate and competition commentary, and any update on full-year guidance direction. Management told analysts after Q1 that the business was tracking toward the upper end of guidance. If that language holds or strengthens, the stock has room to move.
The IRA Wildcard
Worth flagging. Eliquis has been selected for Medicare price negotiations under the Inflation Reduction Act, with maximum fair prices (MFPs) taking effect for the initial negotiation cycle beginning January 1, 2026. Eliquis is the largest single revenue driver in the portfolio, roughly $4.1 billion per quarter in recent reporting. If negotiated pricing cuts into that revenue line more aggressively than management has modeled, it changes the math on the growth portfolio’s ability to fill the gap.
That’s the real downside risk that doesn’t get enough attention in the bull case discussions.
Three Scenarios for July 30
Bull Case
BMY beats Q2 consensus, raises full-year guidance toward the high end, and Opdivo U.S. demand shows signs of stabilization. Camzyos quarterly revenue accelerates and management gives positive color on the adolescent oHCM approval timing. The stock moves through the $62 to $65 resistance zone that has capped multiple rally attempts. Analyst price targets in the $62 to $75 range start looking conservative.
Base Case
Q2 comes in line with expectations. Full-year guidance maintained, perhaps trimmed modestly on the legacy side. Opdivo shows some stabilization but not a clear reacceleration. The stock grinds in the $57 to $62 range as investors await H2 pipeline readouts. The dividend keeps income-oriented buyers engaged, but the multiple stays compressed.
Bear Case
Opdivo declines persist and management cuts full-year guidance. IRA pricing impact on Eliquis turns out larger than disclosed. Legacy erosion accelerates beyond the 12% to 16% model. The stock breaks below $55 support and the patent-cliff concern reasserts itself as the dominant market view. This scenario requires multiple failures at once, which is possible but not the base probability.
Active Trader Framework
BMY is not a momentum stock. It’s a value-oriented pharma name with a catalyst calendar. The July 30 earnings call is the single most important event between now and the Camzyos adolescent FDA decision in September. Watch the Opdivo domestic revenue number first, Eliquis quarterly run rate second, and growth portfolio total as the third confirming data point.
Options implied moves into earnings have been modest relative to biotech peers given BMY’s large-cap, dividend-payer character. That means the risk/reward structure into earnings is somewhat asymmetric: meaningful upside if the growth portfolio beats, limited downside given the stock already trades at a significant discount to sector peers.
The patent cliff story is real. What the market may be underweighting is how much the growth portfolio has already covered it.
For informational and educational purposes only. Not investment advice. Trading involves risk, including loss of principal.
